Diego D. Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diego D. Garcia has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Bonomo
Laboratory on Thymus Research, Rio de Janeiro, Brazil
17 shared publications - Ana Carolina Monteiro
Laboratory of Osteo and Tumor Immunology, Department of Immunobiology, Fluminense Federal University, Niterói, Brazil
17 shared publications - Ana Paula Gregório Alves Fontão
Laboratory on Thymus Research, Rio de Janeiro, Brazil
17 shared publications - Bárbara Du Rocher
Laboratory on Thymus Research, Rio de Janeiro, Brazil
17 shared publications - Cecília Vianna de Andrade
Affiliation Laboratory of Pathology and Cytopathology, Fernandes Figueira National Institute of Women, Child, and Adolescent Health of Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
17 shared publications - Gabriel Fidalgo
Laboratory of Applied Physics to Biomedical and Environmental Sciences, Physics Institute, State University of Rio de Janeiro, Rio de Janeiro 20550-900, Brazil
17 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Data from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Bone metastases represent a common and devastating complication of breast cancer; however, the immune determinants of skeletal colonization, particularly the role of adaptive lymphocyte subsets, have only recently been elucidated. In this study, we identified a nonclassical regulatory role of CD19+ B cells in the modulation of bone remodeling and breast cancer metastatic progression. Using murine models of metastatic 4T1 and nonmetastatic 67NR mammary tumors, we show that 67NR-bearing mice exhibit increased trabecular bone mass, associated with osteoprotegerin (OPG) secretion by CD19+IgD+IgM+CD138− B cells. Functional assays demonstrated that 67NR-primed B cells suppressed bone resorption in vitro and counteracted 4T1-specific T cell–mediated osteolytic activity in vivo. Adoptive transfer of 67NR-primed CD19+ B cells into 4T1-bearing immunocompetent or immunodeficient hosts preserved bone architecture, reduced RANKL production, inhibited metastases, and limited tumor growth. These effects are T cell–independent at the effector phase but require T cell-licensing for the acquisition of the OPG-producing phenotype. Silencing OPG abrogated this protective function. Mechanistically, B cells must be transferred during the early stages of tumor progression to retain their therapeutic potential. Molecular analyses supported the enrichment of RANKL+CD4+ T cells in tumors and lymph nodes, whereas OPG+ B cells were restricted to tumors. Transcriptomic data from The Cancer Genome Atlas further support the prognostic relevance of these immune phenotypes. In a retrospective human cohort, high RANKL+ lymphocyte infiltration in primary tumors correlated with bone metastases, whereas OPG+ infiltration predominated in bone metastasis–free cases. These findings uncover a B cell–driven axis that restrains osteolysis and tumor progression.Significance:This study identifies opposing RANKL+ T cell and OPG-producing B cell immune phenotypes that shape bone metastasis risk in breast cancer. By revealing how these adaptive lymphocyte subsets influence osteolysis and skeletal colonization, our findings define prognostic immune signatures with potential utility for early risk stratification and clinical decision-making.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Bone metastases represent a common and devastating complication of breast cancer; however, the immune determinants of skeletal colonization, particularly the role of adaptive lymphocyte subsets, have only recently been elucidated. In this study, we identified a nonclassical regulatory role of CD19+ B cells in the modulation of bone remodeling and breast cancer metastatic progression. Using murine models of metastatic 4T1 and nonmetastatic 67NR mammary tumors, we show that 67NR-bearing mice exhibit increased trabecular bone mass, associated with osteoprotegerin (OPG) secretion by CD19+IgD+IgM+CD138− B cells. Functional assays demonstrated that 67NR-primed B cells suppressed bone resorption in vitro and counteracted 4T1-specific T cell–mediated osteolytic activity in vivo. Adoptive transfer of 67NR-primed CD19+ B cells into 4T1-bearing immunocompetent or immunodeficient hosts preserved bone architecture, reduced RANKL production, inhibited metastases, and limited tumor growth. These effects are T cell–independent at the effector phase but require T cell-licensing for the acquisition of the OPG-producing phenotype. Silencing OPG abrogated this protective function. Mechanistically, B cells must be transferred during the early stages of tumor progression to retain their therapeutic potential. Molecular analyses supported the enrichment of RANKL+CD4+ T cells in tumors and lymph nodes, whereas OPG+ B cells were restricted to tumors. Transcriptomic data from The Cancer Genome Atlas further support the prognostic relevance of these immune phenotypes. In a retrospective human cohort, high RANKL+ lymphocyte infiltration in primary tumors correlated with bone metastases, whereas OPG+ infiltration predominated in bone metastasis–free cases. These findings uncover a B cell–driven axis that restrains osteolysis and tumor progression.Significance:This study identifies opposing RANKL+ T cell and OPG-producing B cell immune phenotypes that shape bone metastasis risk in breast cancer. By revealing how these adaptive lymphocyte subsets influence osteolysis and skeletal colonization, our findings define prognostic immune signatures with potential utility for early risk stratification and clinical decision-making.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Purity assessment of CD19+ B cells used for adoptive transfer experiments.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Purity assessment of CD19+ B cells used for adoptive transfer experiments.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Early-stage acquisition of a regulatory phenotype by CD19+ B cells from 67NR tumor–bearing mice is required for optimal suppression of 4T1 tumor progression, RANKL production, bone loss, and metastasis. A, Experimental scheme: CD19+ B cells were isolated from the iliac BM of 67NR tumor–bearing BALB/c mice on day 11 after tumor implantation. These cells were transferred intravenously into BALB/c mice injected with 4T1 tumor cells at different time points: day 0, day 7, or day 14 after tumor injection. Mice were euthanized on day 31 for analysis. B, Primary tumor growth was monitored over time, and tumor volume was calculated on the indicated days. C, On day 31, RANKL production was measured by ELISA in supernatants from splenic and BM cell cultures restimulated in vitro with sAg. D, Metastatic burden was evaluated by clonogenic assays in draining LNs and BM. E, Micro-CT analysis of iliac bones was performed to assess structural parameters of trabecular bone, including BV/TV, trabecular separation (Tb.Sp), and trabecular thickness (Tb.Th). Representative 3D reconstructions of trabecular bone are shown below the graphs. Data are shown as mean ± SD (n = 4–5 mice per group), representative of at least two independent experiments. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; Nv, naive control.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Early-stage acquisition of a regulatory phenotype by CD19+ B cells from 67NR tumor–bearing mice is required for optimal suppression of 4T1 tumor progression, RANKL production, bone loss, and metastasis. A, Experimental scheme: CD19+ B cells were isolated from the iliac BM of 67NR tumor–bearing BALB/c mice on day 11 after tumor implantation. These cells were transferred intravenously into BALB/c mice injected with 4T1 tumor cells at different time points: day 0, day 7, or day 14 after tumor injection. Mice were euthanized on day 31 for analysis. B, Primary tumor growth was monitored over time, and tumor volume was calculated on the indicated days. C, On day 31, RANKL production was measured by ELISA in supernatants from splenic and BM cell cultures restimulated in vitro with sAg. D, Metastatic burden was evaluated by clonogenic assays in draining LNs and BM. E, Micro-CT analysis of iliac bones was performed to assess structural parameters of trabecular bone, including BV/TV, trabecular separation (Tb.Sp), and trabecular thickness (Tb.Th). Representative 3D reconstructions of trabecular bone are shown below the graphs. Data are shown as mean ± SD (n = 4–5 mice per group), representative of at least two independent experiments. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; Nv, naive control.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
CD3+ T cells are dispensable for the effector function but required for the acquisition of the regulatory phenotype of CD19+ B cells in vivo. A, Experimental scheme: CD19+ B cells and CD3+ T cells were isolated from the iliac BM of naive or 67NR tumor–bearing BALB/c mice at day 11 after implantation and transferred intravenously into immunocompetent BALB/c recipients implanted with 4T1 tumor cells. Animals were grouped as follows: B Nv/T Nv, B 67NR/T Nv, and B 67NR/T 67NR (B and T cells from 67NR-bearing mice). B, The maximum area of primary tumors was determined using digital caliper measures. Tumor growth was monitored longitudinally and is shown as mean tumor volume (mm3) per group at regular intervals. C, On day 28, clonogenic assays were performed in draining LNs and BM. D, Histomorphometric analysis of sagittal iliac bone sections was performed to assess trabecular bone volume, expressed as a percentage of total tissue volume. E, Experimental scheme in which CD19+ B cells were isolated from the iliac BM of B 67NR or B Nude 67NR mice and transferred into 4T1 tumor–bearing immunocompetent BALB/c recipients. F, Quantification of OPG production by in vitro cultured CD19+ B cells isolated from B 67NR and B Nude 67NR donors. OPG levels were measured in culture supernatants by ELISA after 24 hours. G, RANKL levels were measured by ELISA in the supernatants of LN and BM cells restimulated with 4T1 sAg (sAg) in vitro. H, Primary tumor growth kinetics over time in mice receiving B 67NR or B Nude 67NR cells, compared with tumor-only controls. I, Clonogenic assays quantifying metastatic colonies in LNs and BM on day 28 after transfer. Data are expressed as mean ± SD from two independent experiments with n = 5 mice per group. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
CD3+ T cells are dispensable for the effector function but required for the acquisition of the regulatory phenotype of CD19+ B cells in vivo. A, Experimental scheme: CD19+ B cells and CD3+ T cells were isolated from the iliac BM of naive or 67NR tumor–bearing BALB/c mice at day 11 after implantation and transferred intravenously into immunocompetent BALB/c recipients implanted with 4T1 tumor cells. Animals were grouped as follows: B Nv/T Nv, B 67NR/T Nv, and B 67NR/T 67NR (B and T cells from 67NR-bearing mice). B, The maximum area of primary tumors was determined using digital caliper measures. Tumor growth was monitored longitudinally and is shown as mean tumor volume (mm3) per group at regular intervals. C, On day 28, clonogenic assays were performed in draining LNs and BM. D, Histomorphometric analysis of sagittal iliac bone sections was performed to assess trabecular bone volume, expressed as a percentage of total tissue volume. E, Experimental scheme in which CD19+ B cells were isolated from the iliac BM of B 67NR or B Nude 67NR mice and transferred into 4T1 tumor–bearing immunocompetent BALB/c recipients. F, Quantification of OPG production by in vitro cultured CD19+ B cells isolated from B 67NR and B Nude 67NR donors. OPG levels were measured in culture supernatants by ELISA after 24 hours. G, RANKL levels were measured by ELISA in the supernatants of LN and BM cells restimulated with 4T1 sAg (sAg) in vitro. H, Primary tumor growth kinetics over time in mice receiving B 67NR or B Nude 67NR cells, compared with tumor-only controls. I, Clonogenic assays quantifying metastatic colonies in LNs and BM on day 28 after transfer. Data are expressed as mean ± SD from two independent experiments with n = 5 mice per group. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Tumor-infiltrating CD4+ T and CD19+ B cells from 4T1 and 67NR tumor–bearing mice exhibit distinct RANKL and OPG profiles. A, mRNA expression of Tnfsf11 (RANKL) and Tnfrsf11b (OPG) in CD4+ T and CD19+ B cells isolated from tumors and LNs of mice bearing 4T1 or 67NR tumors, evaluated by qRT-PCR. Results are normalized and expressed as fold change relative to naive controls. B, Quantification of secreted RANKL and OPG in culture supernatants of CD3+ CD4+ T cells (left) and CD19+ B cells (right) restimulated with 4T1 tumor sAg by ELISA. Data are presented as mean ± SD and are representative of two independent experiments (n = 5 mice per group). Statistical significance was considered at P < 0.05. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Tumor-infiltrating CD4+ T and CD19+ B cells from 4T1 and 67NR tumor–bearing mice exhibit distinct RANKL and OPG profiles. A, mRNA expression of Tnfsf11 (RANKL) and Tnfrsf11b (OPG) in CD4+ T and CD19+ B cells isolated from tumors and LNs of mice bearing 4T1 or 67NR tumors, evaluated by qRT-PCR. Results are normalized and expressed as fold change relative to naive controls. B, Quantification of secreted RANKL and OPG in culture supernatants of CD3+ CD4+ T cells (left) and CD19+ B cells (right) restimulated with 4T1 tumor sAg by ELISA. Data are presented as mean ± SD and are representative of two independent experiments (n = 5 mice per group). Statistical significance was considered at P < 0.05. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 8 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Divergent immune signatures defined by RANKL and OPG expression are associated with differential metastatic risk in BRCA-Basal breast tumors. A, Spearman correlation analysis between TNFSF11 (RANKL) gene expression and CD4+ T cell subpopulations in BRCA-Basal tumors (n = 191, TCGA dataset). Significant positive correlations were observed with total CD4+ T cells (EPIC, TIMER), naive and memory subsets (CIBERSORT, XCELL), and Tregs (QUANTISEQ). An inverse correlation with tumor purity suggests an immune (rather than tumor) source of RANKL expression. B,Z-score risk analysis identified high infiltration of CD4+ central memory T cells as significantly associated with increased clinical risk in the BRCA-Basal subtype (Z = 2.253; P < 0.05). C, Spearman correlations between TNFRSF11B (OPG) expression and B cell subpopulations in BRCA-Basal tumors. Significant positive associations were detected with total B cells (QUANTISEQ), naive B cells, and class-switched memory B cells (XCELL), alongside a negative correlation with tumor purity, reinforcing an immune origin for OPG expression. D,Z-score risk analysis revealed that high plasma B cell infiltration was significantly associated with reduced clinical risk (Z = −2.078; P < 0.05), implicating a protective immune profile related to OPG expression. Data were obtained from the TCGA cohort using TIMER 2.0 and analyzed through multiple deconvolution algorithms (EPIC, TIMER, CIBERSORT, XCELL, QUANTISEQ). A and D, Correlation analyses between RANKL (Tnfsf11) or OPG (Tnfrsf11b) expression and immune cell infiltration across the BRCA-Basal TCGA cohort (n = 191) were performed using the TIMER, EPIC, CIBERSORT, XCELL, and QUANTISEQ deconvolution platforms. Statistical significance was determined by Spearman’s rank correlation test. B and C, Clinical risk associations for each immune subset were computed using Z-score analysis (two-tailed). Significance thresholds: P < 0.05.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 8 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Divergent immune signatures defined by RANKL and OPG expression are associated with differential metastatic risk in BRCA-Basal breast tumors. A, Spearman correlation analysis between TNFSF11 (RANKL) gene expression and CD4+ T cell subpopulations in BRCA-Basal tumors (n = 191, TCGA dataset). Significant positive correlations were observed with total CD4+ T cells (EPIC, TIMER), naive and memory subsets (CIBERSORT, XCELL), and Tregs (QUANTISEQ). An inverse correlation with tumor purity suggests an immune (rather than tumor) source of RANKL expression. B,Z-score risk analysis identified high infiltration of CD4+ central memory T cells as significantly associated with increased clinical risk in the BRCA-Basal subtype (Z = 2.253; P < 0.05). C, Spearman correlations between TNFRSF11B (OPG) expression and B cell subpopulations in BRCA-Basal tumors. Significant positive associations were detected with total B cells (QUANTISEQ), naive B cells, and class-switched memory B cells (XCELL), alongside a negative correlation with tumor purity, reinforcing an immune origin for OPG expression. D,Z-score risk analysis revealed that high plasma B cell infiltration was significantly associated with reduced clinical risk (Z = −2.078; P < 0.05), implicating a protective immune profile related to OPG expression. Data were obtained from the TCGA cohort using TIMER 2.0 and analyzed through multiple deconvolution algorithms (EPIC, TIMER, CIBERSORT, XCELL, QUANTISEQ). A and D, Correlation analyses between RANKL (Tnfsf11) or OPG (Tnfrsf11b) expression and immune cell infiltration across the BRCA-Basal TCGA cohort (n = 191) were performed using the TIMER, EPIC, CIBERSORT, XCELL, and QUANTISEQ deconvolution platforms. Statistical significance was determined by Spearman’s rank correlation test. B and C, Clinical risk associations for each immune subset were computed using Z-score analysis (two-tailed). Significance thresholds: P < 0.05.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Research Resource Identifiers (RRIDs) for reagents, antibodies, cell lines, kits, equipment, and software used in this study
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Research Resource Identifiers (RRIDs) for reagents, antibodies, cell lines, kits, equipment, and software used in this study
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
The regulatory phenotype by CD19+ B cells from 67NR tumor-bearing mice does not suppress spleen, liver, and lung metastases.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
The regulatory phenotype by CD19+ B cells from 67NR tumor-bearing mice does not suppress spleen, liver, and lung metastases.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Kinetics of OPG secretion by bone marrow CD19+ B cells from 67NR tumor–bearing mice.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
Kinetics of OPG secretion by bone marrow CD19+ B cells from 67NR tumor–bearing mice.
- Open Access
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
67NR-derived CD19+ IgD+ IgM+ CD138− B cells are the major source of OPG and inhibit in vitro osteoclastogenesis mediated by soluble factors derived from 4T1 tumor CD3+ T cells. A, Quantification of OPG secretion by total BM cells isolated from distinct skeletal sites: femur, tibia, vertebrae, humerus, and calvaria, of tumor-free, 67NR tumor–bearing, and 4T1 tumor–bearing mice at day 35 after implantation. A total of 107 BM cells/mL were cultured in vitro for 12 hours, and OPG levels in supernatants were measured by ELISA. B, CD19+ B cells isolated from the iliac BM of naive, 67NR-bearing, or 4T1-bearing mice were sorted into CD19+ IgD+ IgM+ CD138− (mature cells) and CD19+ IgD− IgM− CD138+ (plasm-like cells) subsets and were cultured in vitro (106 cells/mL) for 12 hours, and OPG levels in supernatants were measured by ELISA. C, Experimental scheme: (i) 11 days after 4T1 tumor cell injection, CD3+ T cells were isolated from iliac BM and stimulated with naive splenic CD11c+ DCs pulsed with 4T1 sAg. Supernatants were harvested after 72 hours of incubation and referred to as CM T 4T1. (ii) Thirty-five days after 67NR tumor cell injection, CD19+ B cells were isolated from iliac BM and stimulated with 4T1 sAg. Supernatants were harvested after 24 hours of incubation and referred to as CM B 67NR. (iii) OC assays were performed with M-CSF plus either RANKL or CM T 4T1, added to naive total BM cells, in the absence or presence of CM B 67NR. D, Quantification of TRAP+ multinucleated OC cells was determined (magnification 40×). E, Functional assessment of OC-mediated resorption using the BD BioCoat Osteologic Bone Cell Culture System. All data are from three independent experiments and are presented as mean ± SD of 4 to 5 mice/group. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
- 13 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
67NR-derived CD19+ IgD+ IgM+ CD138− B cells are the major source of OPG and inhibit in vitro osteoclastogenesis mediated by soluble factors derived from 4T1 tumor CD3+ T cells. A, Quantification of OPG secretion by total BM cells isolated from distinct skeletal sites: femur, tibia, vertebrae, humerus, and calvaria, of tumor-free, 67NR tumor–bearing, and 4T1 tumor–bearing mice at day 35 after implantation. A total of 107 BM cells/mL were cultured in vitro for 12 hours, and OPG levels in supernatants were measured by ELISA. B, CD19+ B cells isolated from the iliac BM of naive, 67NR-bearing, or 4T1-bearing mice were sorted into CD19+ IgD+ IgM+ CD138− (mature cells) and CD19+ IgD− IgM− CD138+ (plasm-like cells) subsets and were cultured in vitro (106 cells/mL) for 12 hours, and OPG levels in supernatants were measured by ELISA. C, Experimental scheme: (i) 11 days after 4T1 tumor cell injection, CD3+ T cells were isolated from iliac BM and stimulated with naive splenic CD11c+ DCs pulsed with 4T1 sAg. Supernatants were harvested after 72 hours of incubation and referred to as CM T 4T1. (ii) Thirty-five days after 67NR tumor cell injection, CD19+ B cells were isolated from iliac BM and stimulated with 4T1 sAg. Supernatants were harvested after 24 hours of incubation and referred to as CM B 67NR. (iii) OC assays were performed with M-CSF plus either RANKL or CM T 4T1, added to naive total BM cells, in the absence or presence of CM B 67NR. D, Quantification of TRAP+ multinucleated OC cells was determined (magnification 40×). E, Functional assessment of OC-mediated resorption using the BD BioCoat Osteologic Bone Cell Culture System. All data are from three independent experiments and are presented as mean ± SD of 4 to 5 mice/group. Statistical comparisons between more than two groups were performed using one-way ANOVA followed by Tukey post hoc test for pairwise comparisons when data were normally distributed. Statistical significance was considered when P < 0.05; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.